{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:42:00Z","timestamp":1781196120170,"version":"3.54.1"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Chimeric antigen receptors are synthetically produced receptors engineered to engage with target cells with high specificity. These cells are created by inserting an artificial T-cell receptor into an immunoglobulin\u2019s antigen-binding region, allowing the cells to combine and target specific antigens. The use of chimeric antigen receptor (CAR) T-cell therapy has been a remarkable achievement in the field of immunotherapy, particularly in the treatment of ophthalmic tumors like retinoblastoma and uveal melanoma. However, there are some documented side effects, such as cytokine release syndrome (CRS) and immunological effector cell-associated neurotoxicity syndrome (ICANS). Additionally, ocular side effects such as blurred vision, vision impairment, and intraocular infections are also concerning and require further evaluation. This review highlights the advances made in chimeric antigen receptor (CAR) immunotherapy, including its structure and manufacture, as well as relevant clinical discoveries and associated adverse effects. By identifying the gaps in current research, this analysis provides insights into potential strategies and solutions for addressing some of the most severe side effects.<\/jats:p>","DOI":"10.1097\/ms9.0000000000002188","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T01:55:21Z","timestamp":1715997321000},"page":"4035-4041","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Adverse events associated with chimeric antigen receptor T-cell therapy in ophthalmology: a narrative review"],"prefix":"10.1097","volume":"86","author":[{"given":"Sara","family":"Sarwar","sequence":"first","affiliation":[{"name":"Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unood","family":"Riaz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraish","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sejal Jain","family":"Kailash","sequence":"additional","affiliation":[{"name":"Department of medicine, Vinnytsia National Medical University, Vinnytsia, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7]]},"reference":[{"key":"R1-20250806","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2478\/ahp-2020-0002","article-title":"A brief history of car-t cells: from laboratory to the bedside","volume":"51","author":"Styczy\u0144ski","year":"2020","journal-title":"Acta Haematol Pol"},{"key":"R2-20250806","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1038\/s41467-021-23817-2","article-title":"P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas","volume":"12","author":"Rousso-Noori","year":"2021","journal-title":"Nat Commun"},{"key":"R3-20250806","doi-asserted-by":"crossref","first-page":"16006","DOI":"10.1038\/mto.2016.6","article-title":"Chimeric antigen receptor T-cell therapy for solid tumors","volume":"3","author":"Newick","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"R4-20250806","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biomedicines9010059","article-title":"Application of car-t cell therapy beyond oncology: autoimmune diseases and viral infections","volume":"9","author":"Zmievskaya","year":"2021","journal-title":"Biomedicines"},{"key":"R5-20250806","doi-asserted-by":"crossref","first-page":"867154","DOI":"10.3389\/fimmu.2022.867154","article-title":"CAR-T therapy for pediatric high-grade gliomas: peculiarities, current investigations and future strategies","volume":"13","author":"Antonucci","year":"2022","journal-title":"Front Immunol"},{"key":"R6-20250806","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41591-020-0827-2","article-title":"Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","volume":"26","author":"Donovan","year":"2020","journal-title":"Nat Med"},{"key":"R7-20250806","first-page":"e17572","article-title":"CD56-chimeric antigen receptor T-cell therapy for refractory\/recurrent rhabdomyosarcoma: a 3.5-year follow-up case report","volume":"98","author":"Jiang","year":"2019","journal-title":"Medicine (United States)"},{"key":"R8-20250806","doi-asserted-by":"crossref","first-page":"e28313","DOI":"10.1002\/pbc.28313","article-title":"VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma","volume":"67","author":"Englisch","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"R9-20250806","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41417-020-00221-4","article-title":"Chimeric antigen receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours","volume":"28","author":"Hsu","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"R10-20250806","doi-asserted-by":"crossref","first-page":"605766","DOI":"10.3389\/fimmu.2021.605766","article-title":"Integrating CAR T-cell therapy and transplantation: comparisons of safety and long-term efficacy of allogeneic hematopoietic stem cell transplantation after CAR T-cell or chemotherapy-based complete remission in B-cell acute lymphoblastic leukemia","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"R12-20250806","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.21037\/atm-20-4502","article-title":"Challenges and strategies of clinical application of CAR-T therapy in the treatment of tumors\u2014a narrative review","volume":"8","author":"Li","year":"2020","journal-title":"Ann Transl Med"},{"key":"R13-20250806","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/bjophthalmol-2021-320814","article-title":"Ocular adverse events associated with chimeric antigen receptor T-cell therapy: A case series and review","volume":"107","author":"Mumtaz","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"R14-20250806","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2013.07.002","article-title":"Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology","volume":"39","author":"Kalos","year":"2013","journal-title":"Immunity"},{"key":"R15-20250806","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"R16-20250806","doi-asserted-by":"crossref","first-page":"720692","DOI":"10.3389\/fphar.2021.720692","article-title":"Chimeric antigen receptor-T cells: a pharmaceutical scope","volume":"12","author":"Hern\u00e1ndez-L\u00f3pez","year":"2021","journal-title":"Front Pharmacol"},{"key":"R17-20250806","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","article-title":"The promise and potential pitfalls of chimeric antigen receptors","volume":"21","author":"Sadelain","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"R18-20250806","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.3390\/jcm12062326","article-title":"CAR T-cell therapy in children with solid tumors","volume":"12","author":"Kulczycka","year":"2023","journal-title":"J Clin Med"},{"key":"R19-20250806","doi-asserted-by":"crossref","first-page":"15021","DOI":"10.1038\/nrdp.2015.21","article-title":"Retinoblastoma","volume":"1","author":"Dimaras","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"R20-20250806","first-page":"961","article-title":"An international survey of classification and treatment choices for group D retinoblastoma","volume":"10","author":"Scelfo","year":"2017","journal-title":"Int J Ophthalmol"},{"key":"R21-20250806","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1186\/s12885-019-6131-1","article-title":"CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing","volume":"19","author":"Andersch","year":"2019","journal-title":"BMC Cancer"},{"key":"R22-20250806","doi-asserted-by":"crossref","first-page":"100971","DOI":"10.1016\/j.tranon.2020.100971","article-title":"GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma\u2014assessing tumor and T cell interaction","volume":"14","author":"Sujjitjoon","year":"2021","journal-title":"Transl Oncol"},{"key":"R23-20250806","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s43018-020-00119-y","article-title":"GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision","volume":"1","author":"Wang","year":"2020","journal-title":"Nat Cancer"},{"key":"R24-20250806","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/08820538.2021.1897857","article-title":"Ophthalmic implications of chimeric antigen receptor T-cell therapy","volume":"36","author":"Chodnicki","year":"2021","journal-title":"Semin Ophthalmol"},{"key":"R25-20250806","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/cncr.29727","article-title":"Uveal melanoma: from diagnosis to treatment and the science in between","volume":"122","author":"Chattopahdyay","year":"2016","journal-title":"Cancer"},{"key":"R26-20250806","doi-asserted-by":"crossref","first-page":"100800","DOI":"10.1016\/j.preteyeres.2019.100800","article-title":"Uveal melanoma: towards a molecular understanding","volume":"75","author":"Smit","year":"2020","journal-title":"Prog Retin Eye Res"},{"key":"R27-20250806","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1158\/0008-5472.CAN-18-3158","article-title":"HER2 CAR-T cells eradicate uveal melanoma and T-cell therapy\u2013resistant human melanoma in IL2 transgenic NOD\/SCID IL2 receptor knockout mice","volume":"79","author":"Forsberg","year":"2019","journal-title":"Cancer Res"},{"key":"R28-20250806","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3390\/cancers15030648","article-title":"Treatment with anti-HER2 chimeric antigen receptor tumor-infiltrating lymphocytes (CAR-TILs) is safe and associated with antitumor efficacy in mice and companion dogs","volume":"15","author":"Forsberg","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R29-20250806","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000513336","article-title":"Clinical trials in metastatic uveal melanoma: immunotherapy","volume":"7","author":"Orloff","year":"2021","journal-title":"Ocul Oncol Pathol"},{"key":"R30-20250806","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T cell therapy for solid tumors: bright future or dark reality?","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol Ther"},{"key":"R31-20250806","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/sj.eye.6701308","article-title":"Ophthalmic manifestations of acute leukaemias: the ophthalmologist\u2019s role","volume":"18","author":"Sharma","year":"2004","journal-title":"Eye (Lond)"},{"key":"R32-20250806","first-page":"2606","article-title":"Recent advances in the treatment of acute lymphoblastic leukemia. Leuk Lymphoma","volume":"60","author":"Rafei","year":"2019"},{"key":"R33-20250806","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1159\/000521200","article-title":"Acute lymphoblastic leukemia relapse limited to the anterior chamber of the eye and treated with novel CAR T-cell therapy","volume":"12","author":"Gomel","year":"2021","journal-title":"Case Rep Ophthalmol"},{"key":"R34-20250806","doi-asserted-by":"crossref","first-page":"e001052","DOI":"10.1136\/jitc-2020-001052","article-title":"Leukemia escape in immune desert: Intraocular relapse of pediatric pro-b-all during systemic control by cd19-car t cells","volume":"8","author":"Willier","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R35-20250806","first-page":"1","article-title":"Hit and run: bilateral massive intraocular lymphomatous infiltration after CAR-T therapy","author":"Abou-Samra","year":"2023","journal-title":"Ocul Immunol Inflamm"},{"key":"R36-20250806","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/ICB.0000000000001246","article-title":"Presumptive recurrence of intra-ocular lymphoma despite chimeric antigen receptor T-cell therapy","volume":"17","author":"Taher","year":"2023","journal-title":"Retin Cases Brief Rep"},{"key":"R37-20250806","first-page":"e10937","article-title":"Isolated intraocular relapse of pediatric B-cell precursor acute lymphoblastic leukaemia following chimeric antigen receptor T-lymphocyte therapy","volume":"12","author":"Veys","year":"2020","journal-title":"Cureus"},{"key":"R38-20250806","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.preteyeres.2013.03.001","article-title":"Optic neuritis in neuromyelitis optica","volume":"36","author":"Levin","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"R39-20250806","doi-asserted-by":"crossref","first-page":"e918","DOI":"10.1212\/NXI.0000000000000918","article-title":"Targeting B cells to modify MS, NMOSD, and MOGAD: Part 1","volume":"8","author":"Graf","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R40-20250806","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R41-20250806","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"R42-20250806","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"R45-20250806","doi-asserted-by":"crossref","first-page":"e796","DOI":"10.1097\/WNO.0000000000001365","article-title":"Leukemic and lymphomatous optic neuropathy: a case series","volume":"41","author":"Lee","year":"2021","journal-title":"J Neuroophthalmol"},{"key":"R46-20250806","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jfma.2021.10.020","article-title":"Optic neuropathy after chimeric antigen receptor T-cell therapy","volume":"121","author":"Huang","year":"2022","journal-title":"J Formosan Med Assoc"},{"key":"R47-20250806","first-page":"e23002","article-title":"Post-CD19 Chimeric Antigen Receptor T-Cell Therapy Cytomegalovirus Retinitis","volume":"14","author":"Bin dokhi","year":"2022","journal-title":"Cureus"},{"key":"R48-20250806","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3390\/curroncol29020044","article-title":"Cytomegalovirus retinitis and retinal detachment following chimeric antigen receptor T cell therapy for relapsed\/refractory multiple myeloma","volume":"29","author":"Zu","year":"2022","journal-title":"Current Oncology"},{"key":"R49-20250806","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1080\/09273948.2021.1889611","article-title":"Varicella Zoster viral retinitis following chimeric antigenic response T-cell therapy for B-cell lymphoma","volume":"30","author":"Alsarhani","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"R50-20250806","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"key":"R51-20250806","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1182\/bloodadvances.2020001450","article-title":"Bilateral retinal detachment after chimeric antigen receptor T-cell therapy","volume":"4","author":"Denton","year":"2020","journal-title":"Blood Adv"},{"key":"R52-20250806","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3928\/23258160-20220124-01","article-title":"Exudative retinal detachment following chimeric antigen receptor T-cell therapy in relapsed B-cell acute lymphoblastic leukemia","volume":"53","author":"Khanna","year":"2022","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R53-20250806","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"R54-20250806","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"key":"R55-20250806","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/hon.3044","article-title":"Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study","volume":"40","author":"Younan","year":"2022","journal-title":"Hematol Oncol"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000002188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:04:51Z","timestamp":1754485491000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000002188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":52,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000002188","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]},"assertion":[{"value":"2023-12-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}